Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million dollars. The announcement comes just two months after the genetic testing company filed for Chapter 11 bankruptcy protection in the U.S. Katherine Ward has this story and more in Health Matters for May 20, 2025.
Health Matters
Health Matters: Regeneron buying 23andMe
More Videos
-
Mouth taping not beneficial despite viral trend, study says
-
Health Matters: FDA tightens COVID vaccine requirements
-
Health Matters: Cases of melanoma on the rise, dermatologists say
-
Health Matters: B.C. opioid rules cut cancer patients’ pain meds, study says
-
Health Matters: Montreal reports sharp increase in tuberculosis, syphilis cases
You are viewing an .
View Original Article